Cure8 trial brief
Hospitalized patients with moderate-to-severe ulcerative colitis flares sometimes need escalation to biologic or surgical treatments. This trial is testing whether a short course of HBOT can improve symptoms and reduce the need for in-hospital escalation by day 5, and whether immune–microbe changes explain benefit.
Adults hospitalized for moderate-to-severe ulcerative colitis flares, IBD clinicians managing inpatients, and researchers interested in HBOT, mucosal hypoxia, or immune–microbiome mechanisms.
This ClinicalTrials.gov record describes a randomized, sham-controlled interventional trial testing hyperbaric oxygen therapy (HBOT) for hospitalized adults with moderate-to-severe ulcerative colitis flares. The active treatment is 2.4 ATA 100% oxygen for 90 minutes once daily for 5 days; the control is a sham compression with room air.
Primary outcome is clinical response by day 5 (resolution of rectal bleeding and improved stool frequency) without need for in-hospital biologics, small molecules, or colectomy. The trial also plans to study immune–microbe mechanisms of response. The registry status is recruiting with planned enrollment of 126 across multiple US centers.
This is a registered interventional trial (recruiting). Previous small randomized trials reported benefit, and this larger study aims to confirm those findings and examine mechanisms. As a trial record, it describes planned interventions and outcomes but does not report results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Ileal pouch disorders are common after IPAA surgery and cause symptoms many patients will experience. Early recognition and initial treatment by primary care can speed symptom relief and identify patients who need...
The study suggests a hidden, early molecular defect that leaves intestinal cells primed to die even during clinical remission, which could help explain why flares recur. Measuring these molecular signals might eventually...
A microbiome-targeted, food-grade supplement could offer a non-immunosuppressive option for people with mild-to-moderate ulcerative colitis who remain inflamed or want to delay immunosuppressive/biologic therapy. The...
